Monty Pal, MD
Dr. Pal is co-director of the Kidney Cancer Program at City of Hope and head of the kidney and bladder cancer disease team at the institution.
Articles by Monty Pal, MD
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Dr. Monty Pal is excited for AUC3 and establishing in-person consensus on new treatment options in urologic cancers.
CheckMate 9ER, 67T and KEYNOTE-564 are discussed.
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Dr. Monty Pal discusses the current IO-refractory RCC space and approaches to patients in the 2nd- and 3rd-line settings.
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
The panel shares how they treat frontline papillary kidney cancer.
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
In a debate series between Brian Rini, MD, and Monty Pal, MD, they discuss frontline RCC treatment options.
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
The panel discusses outcomes from the CheckMate-9ER trial and addresses the importance depth of response.
The panel compares three TKI/IO treatment combinations.
The panel discusses considerations for treatment choice in patients with poor- and intermediate-risk disease.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.